Evaluation of efficacy of Sitafloxacin in treatment of moderate to severe acute rhinosinusitis
Not Applicable
- Conditions
- acute rhinosinusitis
- Registration Number
- JPRN-UMIN000009567
- Lead Sponsor
- Wakayama-Okayama Otolaryngology Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients with history of hypersensitivity to quinolone (2) Patients with history of convulsive disorder (e.g. Epilepsy) (3)Pregnant or lactating women (4)Severe heart diseases or hepatic dysfunction (5) Moderate or severe renal dysfunction (6) Severe underlying disease; patients in which clinical evaluation is difficult because of confounding diseases (7) Patients showing improvement of symptoms by the other antibiotic therapy (8) Administration of Sitafloxacin 7 days before starting Sitafloxacin (9)For other reasons, patients determined to be inappropriate for study entry by investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical efficacy judged by the scoring system at the end of the medication or at the end of observation period
- Secondary Outcome Measures
Name Time Method Bacteriological efficacy at the end of the medication or at the end of observation period